Zacks Investment Research upgraded shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) from a sell rating to a hold rating in a report released on Tuesday morning.

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

ACRS has been the topic of several other research reports. Jefferies Group raised their target price on Aclaris Therapeutics from $23.00 to $31.00 and gave the stock a buy rating in a research report on Monday, September 19th. JMP Securities initiated coverage on Aclaris Therapeutics in a research report on Friday, September 30th. They set an outperform rating and a $34.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of Buy and a consensus price target of $31.80.

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Aclaris Therapeutics (NASDAQ:ACRS) traded up 0.62% during midday trading on Tuesday, reaching $22.84. The company’s stock had a trading volume of 1,770 shares. The stock’s 50 day moving average is $23.72 and its 200 day moving average is $20.83. Aclaris Therapeutics has a 12-month low of $12.99 and a 12-month high of $33.88. The stock’s market cap is $489.12 million.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its earnings results on Thursday, August 11th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.01. Analysts anticipate that Aclaris Therapeutics will post ($2.60) earnings per share for the current year.

In other news, insider Kamil Ali-Jackson sold 1,841 shares of the business’s stock in a transaction that occurred on Wednesday, September 28th. The stock was sold at an average price of $24.66, for a total value of $45,399.06. Following the transaction, the insider now owns 77,798 shares of the company’s stock, valued at $1,918,498.68. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Ra Capital Management, Llc sold 525,550 shares of the business’s stock in a transaction that occurred on Friday, September 16th. The shares were sold at an average price of $24.19, for a total value of $12,713,054.50. The disclosure for this sale can be found here. 46.40% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ACRS. Nationwide Fund Advisors raised its position in Aclaris Therapeutics by 47.0% in the second quarter. Nationwide Fund Advisors now owns 5,747 shares of the company’s stock worth $106,000 after buying an additional 1,838 shares during the last quarter. Tocqueville Asset Management L.P. acquired a new stake in Aclaris Therapeutics during the second quarter worth $185,000. Teachers Advisors Inc. increased its stake in Aclaris Therapeutics by 91.0% in the second quarter. Teachers Advisors Inc. now owns 14,212 shares of the company’s stock worth $262,000 after buying an additional 6,772 shares during the period. Swiss National Bank acquired a new stake in Aclaris Therapeutics during the second quarter worth $283,000. Finally, Sabby Management LLC acquired a new stake in Aclaris Therapeutics during the second quarter worth $292,000. 71.39% of the stock is currently owned by institutional investors and hedge funds.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

5 Day Chart for NASDAQ:ACRS

Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.